Skip to main content
Top
Published in: Supportive Care in Cancer 7/2013

01-07-2013 | Original Article

Pancreatic cancer and supportive care—pancreatic exocrine insufficiency negatively impacts on quality of life

Authors: H. M. Gooden, K. J. White

Published in: Supportive Care in Cancer | Issue 7/2013

Login to get access

Abstract

Purpose

Pancreatic cancer is a fatal cancer with a median survival from diagnosis of around 5 months Speer et al. (Med J Aust 196(8):511–515, 2012). Given the short survival time for people with pancreatic cancer, effective supportive care is imperative to enable best quality of life. This article presents an unexpected finding from research into the psychosocial supportive care needs of people affected by pancreatic cancer that management of pancreatic exocrine insufficiency is an area of unmet need that severely impacts on quality of life and increases carer burden in people affected by pancreatic cancer.

Methods

A qualitative inquiry framework was used to explore participants’ perspectives and experience. Two groups of participants (N = 35) were recruited across Australia from people accessing the Cancer Helpline or direct referral from clinicians/nurses: patients diagnosed with pancreatic cancer (N = 12) and carers/family (N = 23) including a subgroup of bereaved participants (N = 14). Sampling continued until saturation. A thematic content analysis was conducted.

Results

The findings revealed that the major quality of life theme was difficulty in managing gut symptoms and complex dietary issues. Issues were related to lack of information about malabsorption and managing symptoms of pancreatic exocrine insufficiency. This was compounded by a lack of routine dietary consultation: perceived reluctance of clinicians to prescribe enzyme supplements and poor understanding of dose to diet guidelines.

Conclusion

Participants expressed distress relating to the effects of pancreatic exocrine insufficiency. Pancreatic enzyme supplement therapy with clear dosage guidelines and associated dietary advice could resolve symptoms of malabsorption and markedly improve quality of life. For people affected by pancreatic cancer, this is an essential supportive care.
Literature
1.
go back to reference Speer AG et al (2012) Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. Med J Aust 196(8):511–515PubMedCrossRef Speer AG et al (2012) Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. Med J Aust 196(8):511–515PubMedCrossRef
2.
go back to reference American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta
3.
go back to reference Australian Institute of Health and Welfare and Australasian Association of Cancer Registries (2008) Cancer in Australia: an overview 2008. Australian Institute of Health and Welfare, Canberra Australian Institute of Health and Welfare and Australasian Association of Cancer Registries (2008) Cancer in Australia: an overview 2008. Australian Institute of Health and Welfare, Canberra
4.
go back to reference Nieto J, Grossbard ML, Kozuch P (2008) Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 2008(13):562–576CrossRef Nieto J, Grossbard ML, Kozuch P (2008) Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 2008(13):562–576CrossRef
6.
go back to reference Robotin MC et al (2010) Defining research priorities for pancreatic cancer in Australia: results of a consensus development process. Cancer Causes Control 21(5):729–736PubMedCrossRef Robotin MC et al (2010) Defining research priorities for pancreatic cancer in Australia: results of a consensus development process. Cancer Causes Control 21(5):729–736PubMedCrossRef
7.
go back to reference Turoff M (1975) The policy Delphi. In: Linstone H, Turoff M (eds) The Delphi method: techniques and applications. Addison-Wesley, Boston, pp 84–101 Turoff M (1975) The policy Delphi. In: Linstone H, Turoff M (eds) The Delphi method: techniques and applications. Addison-Wesley, Boston, pp 84–101
8.
go back to reference Saunders C et al (2009) As the bell tolls: a foundation study on pancreatic cancer consumer's research priorities. BMC Res Notes 2:179–188PubMedCrossRef Saunders C et al (2009) As the bell tolls: a foundation study on pancreatic cancer consumer's research priorities. BMC Res Notes 2:179–188PubMedCrossRef
9.
go back to reference Biankin AV et al (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 137(2):558–568.e11PubMedCrossRef Biankin AV et al (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 137(2):558–568.e11PubMedCrossRef
10.
go back to reference Chang DK et al (2008) Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem? J Gastroenterol Hepatol 23(7 Pt 1):1036–1045PubMedCrossRef Chang DK et al (2008) Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem? J Gastroenterol Hepatol 23(7 Pt 1):1036–1045PubMedCrossRef
11.
go back to reference Colvin EK et al (2008) Individualizing therapy for pancreatic cancer. J Gastroenterol Hepatol 23(12):1779–1782PubMedCrossRef Colvin EK et al (2008) Individualizing therapy for pancreatic cancer. J Gastroenterol Hepatol 23(12):1779–1782PubMedCrossRef
12.
go back to reference Lowery MA, O'Reilly EM (2012) Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J 12(1):1–9PubMedCrossRef Lowery MA, O'Reilly EM (2012) Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J 12(1):1–9PubMedCrossRef
13.
go back to reference Petrin K et al (2009) Adjusting to pancreatic cancer: perspectives from first-degree relatives. Palliat Support Care 7(3):281–288PubMedCrossRef Petrin K et al (2009) Adjusting to pancreatic cancer: perspectives from first-degree relatives. Palliat Support Care 7(3):281–288PubMedCrossRef
14.
go back to reference Sharma C et al (2011) Adjuvant therapy of pancreatic cancer. J Pancreas 12(4):343–346 Sharma C et al (2011) Adjuvant therapy of pancreatic cancer. J Pancreas 12(4):343–346
15.
go back to reference Romanus D et al (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43(2):205–217PubMedCrossRef Romanus D et al (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43(2):205–217PubMedCrossRef
16.
go back to reference Jamieson NB et al (2011) Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 17(10):3316–3331PubMedCrossRef Jamieson NB et al (2011) Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 17(10):3316–3331PubMedCrossRef
17.
go back to reference Collisson EA et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17(4):500–503PubMedCrossRef Collisson EA et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17(4):500–503PubMedCrossRef
18.
go back to reference Renouf D, Moore M (2010) Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 10(4):529–540PubMedCrossRef Renouf D, Moore M (2010) Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 10(4):529–540PubMedCrossRef
19.
go back to reference Harinck F et al (2010) Is early diagnosis of pancreatic cancer fiction? Surveillance of individuals at high risk for pancreatic cancer. Dig Dis 28(4–5):670–678PubMedCrossRef Harinck F et al (2010) Is early diagnosis of pancreatic cancer fiction? Surveillance of individuals at high risk for pancreatic cancer. Dig Dis 28(4–5):670–678PubMedCrossRef
20.
go back to reference Stapley S et al (2012) The risk of pancreatic cancer in symptomatic patients in primary care: a large case–control study using electronic records. Br J Cancer 106(12):1940–1944PubMedCrossRef Stapley S et al (2012) The risk of pancreatic cancer in symptomatic patients in primary care: a large case–control study using electronic records. Br J Cancer 106(12):1940–1944PubMedCrossRef
21.
go back to reference Bachet JB, Marechal R, van Laethem JL (2011) Treatment of pancreatic cancer: what can we really predict today? Cancer 3(1):675–699 Bachet JB, Marechal R, van Laethem JL (2011) Treatment of pancreatic cancer: what can we really predict today? Cancer 3(1):675–699
22.
go back to reference Stathis A, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172PubMedCrossRef Stathis A, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172PubMedCrossRef
24.
go back to reference Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psychooncology 10:19–28PubMedCrossRef Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psychooncology 10:19–28PubMedCrossRef
25.
go back to reference Clark KL et al (2010) Psychological distress in patients with pancreatic cancer–an understudied group. Psychooncology 19(12):1313–1320PubMedCrossRef Clark KL et al (2010) Psychological distress in patients with pancreatic cancer–an understudied group. Psychooncology 19(12):1313–1320PubMedCrossRef
26.
go back to reference Jia L et al (2010) Investigation of the incidence of pancreatic cancer-related depression and its relationship with the quality of life of patients. Digestion 82(1):4–9PubMedCrossRef Jia L et al (2010) Investigation of the incidence of pancreatic cancer-related depression and its relationship with the quality of life of patients. Digestion 82(1):4–9PubMedCrossRef
27.
go back to reference Pappas S, Krzywda E, McDowell N (2010) Nutrition and pancreaticoduodenectomy. Nutr Clin Pract 25(3):234–243PubMedCrossRef Pappas S, Krzywda E, McDowell N (2010) Nutrition and pancreaticoduodenectomy. Nutr Clin Pract 25(3):234–243PubMedCrossRef
28.
go back to reference Damerla V et al (2008) Pancreatic enzyme supplementation in pancreatic cancer. J Support Oncol 6(8):393–396PubMed Damerla V et al (2008) Pancreatic enzyme supplementation in pancreatic cancer. J Support Oncol 6(8):393–396PubMed
29.
go back to reference Davidson W et al (2004) Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 23(2):239–247PubMedCrossRef Davidson W et al (2004) Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 23(2):239–247PubMedCrossRef
30.
go back to reference DiMagno EP, Malagelada JR, Go VL (1979) The relationships between pancreatic ductal obstruction and pancreatic secretion in man. Mayo Clin Proc 54(3):157–162PubMed DiMagno EP, Malagelada JR, Go VL (1979) The relationships between pancreatic ductal obstruction and pancreatic secretion in man. Mayo Clin Proc 54(3):157–162PubMed
31.
go back to reference Dominguez-Munoz JE (2011) Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol 26(Suppl 2):12–16PubMedCrossRef Dominguez-Munoz JE (2011) Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol 26(Suppl 2):12–16PubMedCrossRef
32.
go back to reference Bachmann J et al (2008) Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 12(7):1193–1201PubMedCrossRef Bachmann J et al (2008) Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 12(7):1193–1201PubMedCrossRef
33.
go back to reference Birkmeyer JD et al (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346(15):1128–1137PubMedCrossRef Birkmeyer JD et al (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346(15):1128–1137PubMedCrossRef
34.
go back to reference Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364(22):2128–2137PubMedCrossRef Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364(22):2128–2137PubMedCrossRef
35.
go back to reference Fennell ML et al (2010) The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. JNCI Monogr 2010(40):72–80CrossRef Fennell ML et al (2010) The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. JNCI Monogr 2010(40):72–80CrossRef
36.
go back to reference de Wilde RF et al (2012) Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 99(3):404–410PubMedCrossRef de Wilde RF et al (2012) Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 99(3):404–410PubMedCrossRef
37.
go back to reference Gooiker GA et al (2011) Systematic review and meta-analysis of the volume–outcome relationship in pancreatic surgery. Br J Surg 98(4):485–494PubMedCrossRef Gooiker GA et al (2011) Systematic review and meta-analysis of the volume–outcome relationship in pancreatic surgery. Br J Surg 98(4):485–494PubMedCrossRef
39.
go back to reference Toouli J et al (2010) Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust 193(8):461–467PubMed Toouli J et al (2010) Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust 193(8):461–467PubMed
Metadata
Title
Pancreatic cancer and supportive care—pancreatic exocrine insufficiency negatively impacts on quality of life
Authors
H. M. Gooden
K. J. White
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1729-3

Other articles of this Issue 7/2013

Supportive Care in Cancer 7/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine